Company description

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insig hts derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates. Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder, or MDD, bipolar depression, or BPD, treatment resistant depression, or TRD, schizophrenia, and Parkinson’s disease. Each of our programs, including our most advanced program — ALTO-207, are supported by robust clinical data in the respective patient populations in which we are developing them. Mental health conditions are a leading cause of disability globally. In the United States, current estimates suggest that 13% of adults take antidepressants and over 50% of the population will be diagnosed with a psychiatric disorder during their lifetime, with an estimated $280 billion spent on mental health services in 2020. We believe limitations of currently available treatments, which are often ineffective in a large portion of patients, are a key driver of these rising costs. We believe better outcomes can be achieved through precision medications tailored specifi cally to address heterogenous alterations in brain functioning seen across individual patients within any psychiatric diagnosis.

Read the full filing description · filed 16 Mar 2026

At a glance

Sector

Healthcare

Industry

Pharmaceutical Preparations